__timestamp | Geron Corporation | HUTCHMED (China) Limited |
---|---|---|
Wednesday, January 1, 2014 | 16758000 | 26684000 |
Thursday, January 1, 2015 | 17793000 | 29829000 |
Friday, January 1, 2016 | 18761000 | 39578000 |
Sunday, January 1, 2017 | 19287000 | 43277000 |
Monday, January 1, 2018 | 18707000 | 48645000 |
Tuesday, January 1, 2019 | 20893000 | 52934000 |
Wednesday, January 1, 2020 | 25678000 | 61349000 |
Friday, January 1, 2021 | 29665000 | 127125000 |
Saturday, January 1, 2022 | 43628000 | 136106000 |
Sunday, January 1, 2023 | 69135000 | 133175999 |
Cracking the code
In the ever-evolving landscape of corporate finance, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart provides a decade-long insight into the SG&A expenses of HUTCHMED (China) Limited and Geron Corporation, two prominent players in their respective industries.
From 2014 to 2023, HUTCHMED (China) Limited has seen its SG&A expenses grow by approximately 400%, peaking in 2022. This reflects a strategic expansion and investment in administrative capabilities. In contrast, Geron Corporation's expenses have increased by around 300% over the same period, indicating a more conservative approach.
Understanding these trends is vital for investors and analysts. HUTCHMED's aggressive spending could signal growth opportunities, while Geron's steadier increase might suggest a focus on sustainable development. These insights are invaluable for stakeholders aiming to make informed decisions in a competitive market.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.